Loading company…
Transition Bio develops drug discovery technology for complex diseases, including cancer and neurodegenerative conditions.
Founded by Samuel Cohen and based in Watertown, Massachusetts, Transition Bio uses droplet microfluidics and cellular imaging in its drug discovery platform. It works with biopharmaceutical companies and research institutions on therapeutics for oncology, neurodegenerative conditions, and inflammation. In October 2024, it raised USD 13.265 mn in Series A funding from Bristol-Myers Squibb Company and Northpond Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in